

Multiple Sclerosis
Self-Injectable Agents (drugs E-Z)
(Extavia®, Rebif®, Plegridy®)



Prescriber + Shipping Information

Patient name: _____ DOB: _____
 Sex: Female Male SSN: _____
 Language: _____ Wt: _____ kg lbs Ht: _____ cm in
 Address: _____
 Apt/Suite: _____ City: _____ State: _____ Zip: _____
 Phone: _____ Alternate: _____
 Caregiver name: _____ Relation: _____
 Local pharmacy: _____ Phone: _____
 Insurance plan: _____ Plan ID: _____
 Please fax a copy of front and back of the insurance card(s).

Prescriber name: _____
 NPI: _____
 Address: _____
 Apt/Suite: _____ City: _____ State: _____ Zip: _____
 Contact: _____
 Phone: _____ Alternate: _____
 Fax: _____
 Email: _____
 If shipping to prescriber: First Fill Always Never

Clinical Information (Please fax all pertinent clinical and lab information)

Diagnosis: G35 (Multiple Sclerosis) _____ Diagnosis Date: _____
 Type: Clinically isolated syndrome Relapsing-remitting Secondary-progressive Primary-progressive Progressive-relapsing
 Hepatic Impairment present: Yes No AST: _____ U/L ALT: _____ U/L Bilirubin: _____ mg/dL Lab date: _____
 Pre-existing hepatic conditions: HBV HCV _____ TB Test: Positive Negative Test date: _____

| Prior Therapy <input type="checkbox"/> Yes <input type="checkbox"/> No | Reason for Discontinuation of Therapy | Approximate Start Date | Approximate End Date |
|--|---------------------------------------|------------------------|----------------------|
| _____ | _____ | _____ | _____ |
| _____ | _____ | _____ | _____ |

Comorbidities: _____
 Concomitant Medications: _____
 Allergies: NKDA Other: _____

| Prescription | | Quantity | Refill |
|--|--|---------------------------|----------------------|
| <i>§ Avonex®, Betaseron®, Copaxone® are available on the Multiple Sclerosis - Self-Injectable Agents Enrollment Form A-D §</i> | | | |
| Extavia® (interferon beta-1b) | Week 1-2: Inject 0.0625 mg (0.25 mL) subcut every other day; Week 3-4: Inject 0.125 mg (0.5 mL) subcut every other day. | 15 x 0.3 mg | Vials |
| | Week 5-6: Inject 0.1875 mg (0.75 mL) subcut every other day; Week 7-onward: Inject 0.25 mg (1 mL) subcut every other day. | 15 x 0.3 mg | Vials |
| | Inject 0.25 mg (1 mL) subcut every other day | 15 x 0.3 mg | Vials |
| Rebif® (interferon beta-1a) | Week 1-2: Inject 4.4 mcg (0.1 mL) subcut three times per week; Week 3-4: Inject 11 mcg (0.25 mL) subcut three times per week. | 6 x 8.8 mcg 6 x 22 mcg | PFS |
| | Week 5 and thereafter: Inject 22 mcg subcut three times per week | 12 x 22 mcg | Autoinjectors PFS |
| | Week 1-2: Inject 8.8 mcg (0.2 mL) subcut three times per week; Week 3-4: Inject 22 mcg (0.5 mL) subcut three times per week. | 6 x 8.8 mcg 6 x 22 mcg | Autoinjectors PFS |
| | Week 5 and thereafter: Inject 44 mcg subcut three times per week | 12 x 44 mcg | Autoinjectors PFS |
| Plegridy® (peginterferon beta-1a) | Inject 63 mcg subcut on day 1; then inject 94 mcg on day 15 | 1 x 63 mcg 1 x 94 mcg | Pens PFS |
| | Inject 125 mcg subcut on day 29 and every two weeks thereafter | 2 x 125 mcg | Pens PFS |

Injection Training Provided by: Prescriber's Office Pharmacy Other: _____

For patients requiring immune globulin therapy, please fill out the respective form: [IVIg](#) or [SCIg](#).

Per state-specific law, prescriptions will be dispensed as generic, if applicable, unless notated otherwise: _____

Stamp signature not allowed, physician signature required.

Prescriber's Signature: _____ Date: _____
 I authorize Diplomat Pharmacy, Inc. and its representatives to act as an agent to initiate and execute the insurance prior authorization process for this prescription and any future fills of the same prescription for the patient listed above. I understand that I can revoke this designation at any time by providing written notice to Diplomat Pharmacy, Inc.

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately by calling 810.768.9178 or by emailing compliance@diplomat.is to obtain instructions as to the proper destruction of the transmitted material. Thank you.